Business
Halberd Eliminates E. Coli in 20 Minutes Vs. 7-10 Days with Conventional Antibiotics
Halberd Eliminates E. Coli in 20 Minutes Vs. 7-10 Days with Conventional Antibiotics.
About this update from Halberd Corp.
[{"type":"text","content":"Jackson Center, Pennsylvania--(Newsfile Corp. - April 18, 2022) - Halberd Corporation (OTC PINK: HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This compares to up to 10 days using conventional antibiotic treatments as the current standard of care. E. coli (Escherichia coli) is the leading cause of urinary tract, ear, wound and other infections in humans[1] and has been shown to develop antibiotic resistance in as little as 11 days.[2]Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, \"Our current goal is to fine tune the strategies for a few of the antigens before commencing with blood serum and animal testing. The Halberd technology has the potential for being a tremendous paradigm shift in the treatment of infectious diseases. The standard treatment for meningitis by administration of gentamicin can take 7-10 days for the completion of treatment. Halberd showed the eradication of 96% of E. coli bacteria in CSF in only twenty minutes in vitro. The rapid results from Halberd's treatment could significantly improve patient recovery and survivability from meningitis and blood sepsis, which together kill about 40,000 people each year in the United States alone[3],[4].E. coli petri dishes and graphsTo view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7041/120680_b5c52dab54bbe818_001full.jpg\"Gentamicin, a popular drug for the treatment of E. coli related conditions, such as meningitis or blood sepsis, is also notorious for causing subsequent hearing loss in the patient. There is a significant chance that an infant with meningitis will subsequently be deaf for life, even after a \"successful\" antibiotic treatment. Once fully developed, the Halberd approach should have none of these complications and should cost a small fraction of traditional antibiotic treatments. Finally, there is, and will never be the development of resistance against a laser and/or radiofrequency by an infectious pathogen.\"William A. Hartman, Halberd's Chairman, President & CEO added, \"This latest testing ...